Stockscreener 앱 받기
139.49
1.94%
-2.76
시간 외 거래:
138.00
-1.49
-1.07%
전일 마감가:
$142.25
열려 있는:
$141.97
하루 거래량:
1.74M
Relative Volume:
1.41
시가총액:
$14.18B
수익:
$3.10B
순이익/손실:
$668.60M
주가수익비율:
21.45
EPS:
6.5044
순현금흐름:
$831.30M
1주 성능:
-6.70%
1개월 성능:
-8.57%
6개월 성능:
+9.79%
1년 성능:
-4.72%
1일 변동 폭
$139.32
$142.25
1주일 범위
$139.32
$152.63
52주 변동 폭
$122.14
$186.12
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
139.49 | 14.46B | 3.10B | 668.60M | 831.30M | 6.5044 |
TAK
Takeda Pharmaceutical Co Adr
|
18.81 | 60.52B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.01 | 46.09B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.11 | 40.68B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.61 | 30.11B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
489.42 | 21.34B | 3.17B | 1.29B | 1.01B | 27.09 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-04-15 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-14 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 재개 | Citigroup | Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 재확인 | Mizuho | Neutral |
| 2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-09-26 | 개시 | Wells Fargo | Equal Weight |
| 2022-06-06 | 재개 | Jefferies | Buy |
| 2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 개시 | BMO Capital Markets | Underperform |
| 2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 개시 | Raymond James | Outperform |
| 2020-09-30 | 개시 | The Benchmark Company | Hold |
| 2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-06-09 | 개시 | Wedbush | Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-24 | 개시 | William Blair | Outperform |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-05 | 개시 | Guggenheim | Neutral |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-02-06 | 재확인 | BofA/Merrill | Buy |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit - Yahoo Finance
Trading Systems Reacting to (NBIX) Volatility - Stock Traders Daily
Zacks.com featured highlights include NVIDIA, Neurocrine Biosciences and Ball - easternprogress.com
RBC Cuts Price Target on Neurocrine Biosciences to $187 From $198, Keeps Outperform Rating - marketscreener.com
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a Promising 43% Potential Upside - DirectorsTalk Interviews
Neurocrine Biosciences stock draws support from strong Q2 figures - AD HOC NEWS
Is Phase 4 Success Altering The Investment Case For Neurocrine Biosciences Stock? - simplywall.st
NEUROCRINE BIOSCIENCES INC (NASDAQ: NBIX) Grants 3,587 Shares to CSO Onyia Jude at No Cost - Kalkine Media
Neurocrine Biosciences chief corp. affairs officer David Boyer sells $130k in stock - Investing.com Nigeria
Neurocrine Biosciences Inc (NBIX) Shares Fall 4.6% -- What GF Sc - GuruFocus
Neurocrine Biosciences (NBIX) CMO reports stock vesting, no market sale - Stock Titan
Neurocrine Biosciences (NASDAQ: NBIX) director logs 14,343-share vesting, 7,839 withheld for taxes - Stock Titan
Performance grant hands 4,483 shares to Neurocrine (NBIX) regulatory chief - Stock Titan
Neurocrine Biosciences (NBIX) grants HR chief 3,587 shares - Stock Titan
PRSU vest gives Neurocrine Biosciences (NBIX) officer 3,587 shares - Stock Titan
CFO at Neurocrine Biosciences (NBIX) sells shares after performance award vests - Stock Titan
Is Neurocrine Biosciences (NBIX) Still Undervalued As It Heads Into September Conferences? - simplywall.st
Neurocrine (NASDAQ: NBIX) officer signals potential $361K stock sale - Stock Titan
Neurocrine (NASDAQ: NBIX) officer plans $736K stock sale - Stock Titan
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring A 34.93% Potential Upside - DirectorsTalk Interviews
NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings - Stocktwits
Behavioral Patterns of NBIX and Institutional Flows - Stock Traders Daily
ETFs Investing in Neurocrine Biosciences, Inc. Stocks - TradingView
Neurocrine Biosciences CCO Eric Benevich sells $333k in stock By Investing.com - Investing.com Australia
Neurocrine Biosciences at Cantor healthcare conference: growth broadens By Investing.com - Investing.com Nigeria
Transcript : Neurocrine Biosciences, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 08:35 AM - marketscreener.com
Neurocrine Biosciences at Wells Fargo conference: growth story broadens By Investing.com - Investing.com Canada
Officer at Neurocrine (NASDAQ: NBIX) plans 2,154-share sale in 2026 - Stock Titan
Neurocrine Biosciences at Wells Fargo conference: growth story broadens - Investing.com
Neurocrine Biosciences stock rating reaffirmed by RBC Capital - Investing.com Nigeria
How Advancing NBI-1117567 to Phase 2 and a $10M Milestone Will Impact Neurocrine Biosciences (NBIX) Investors - simplywall.st
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a 36% Upside Potential with Robust Revenue Growth - DirectorsTalk Interviews
Neurocrine Biosciences (NBIX) Stock Could Still Be A Bargain After A 61% Run - simplywall.st
Neurocrine (NBIX) director donates 1,000 shares - Stock Titan
Neurocrine Biosciences Inc. (NBIX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September - PR Newswire
Resilient Neurocrine Biosciences stock holds firm as Crenessity sales surge and valuation stretches - AD HOC NEWS
Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go? - Yahoo Finance
Neurocrine Biosciences (NASDAQ:NBIX): An Affordable Growth Stock With Strong Momentum and Valuation - ChartMill
Neurocrine Biosciences (NBIX) Cleared An FDA Milestone, Is It Trading At A Discount? - simplywall.st
How Investors May Respond To Neurocrine Biosciences (NBIX) Phase 4 INGREZZA Patient-Reported Benefit Data - Sahm
Did Nxera’s Alzheimer’s Milestone and IND Progress Just Shift Neurocrine Biosciences' (NBIX) Investment Narrative? - Yahoo Finance
Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition - Yahoo Finance
Neurocrine Biosciences (NBIX) Stock Still Looks Like A Bargain Following Its 59% Run - simplywall.st
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a 38.67% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Neurocrine Biosciences Stock: 'House Full Of Options' (NASDAQ:NBIX) - Seeking Alpha
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Eastern Progress
Zacks Investment ResearchGlobes - Globes - Israel Business News
Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last? - Yahoo Finance
Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth? - Yahoo Finance
Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation? - Yahoo Finance Singapore
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
뉴로크린 바이오사이언시스 주식 (NBIX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ABERNETHY MATT | Chief Financial Officer |
Sep 14 '26 |
Sale |
157.20 |
2,311 |
363,285 |
42,808 |
1.57%
자본화:
|
볼륨(24시간):